Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™
Vivos Inc. (OTCQB: RDGL) has announced the certification of the University of Florida Veterinary Hospital to offer IsoPet® Precision Radionuclide Therapy™, a targeted cancer treatment for animals. This innovative therapy uses a proprietary radionuclide injection to treat solid tumors in pets, offering a minimally invasive alternative to traditional treatments.
The certification marks an expansion in Vivos' network of certified clinics, with the company providing comprehensive support through the licensing process and training to ensure safe and effective administration of IsoPet therapy. Additional veterinary hospitals are currently in the certification pipeline as part of the company's growth strategy.
Vivos Inc. (OTCQB: RDGL) ha annunciato la certificazione del University of Florida Veterinary Hospital per offrire la IsoPet® Precision Radionuclide Therapy™, un trattamento mirato contro il cancro negli animali. Questa terapia innovativa utilizza un'iniezione proprietaria di radionuclidi per trattare i tumori solidi negli animali domestici, offrendo un'alternativa minimamente invasiva ai trattamenti tradizionali.
La certificazione rappresenta un'espansione della rete di cliniche certificate di Vivos, con l'azienda che fornisce supporto completo durante il processo di licenza e formazione per garantire una somministrazione sicura ed efficace della terapia IsoPet. Altri ospedali veterinari sono attualmente in fase di certificazione come parte della strategia di crescita dell'azienda.
Vivos Inc. (OTCQB: RDGL) ha anunciado la certificación del University of Florida Veterinary Hospital para ofrecer la IsoPet® Precision Radionuclide Therapy™, un tratamiento oncológico dirigido para animales. Esta innovadora terapia utiliza una inyección patentada de radionúclidos para tratar tumores sólidos en mascotas, ofreciendo una alternativa mínimamente invasiva a los tratamientos tradicionales.
La certificación marca una expansión en la red de clínicas certificadas de Vivos, con la empresa proporcionando apoyo integral durante el proceso de licenciamiento y capacitación para asegurar una administración segura y eficaz de la terapia IsoPet. Actualmente, otros hospitales veterinarios están en proceso de certificación como parte de la estrategia de crecimiento de la compañía.
Vivos Inc. (OTCQB: RDGL)는 University of Florida Veterinary Hospital가 IsoPet® Precision Radionuclide Therapy™를 제공할 수 있도록 인증했다고 발표했습니다. 이 혁신적인 치료법은 반려동물의 고형 종양을 치료하기 위해 독점 방사성핵종 주사를 사용하며, 기존 치료법에 비해 최소 침습적인 대안을 제공합니다.
이번 인증은 Vivos의 인증 클리닉 네트워크 확장을 의미하며, 회사는 라이선스 과정과 교육을 통해 IsoPet 치료의 안전하고 효과적인 시행을 지원하고 있습니다. 현재 추가 수의학 병원들이 회사의 성장 전략의 일환으로 인증 절차를 진행 중입니다.
Vivos Inc. (OTCQB : RDGL) a annoncé la certification du University of Florida Veterinary Hospital pour proposer la IsoPet® Precision Radionuclide Therapy™, un traitement ciblé contre le cancer pour les animaux. Cette thérapie innovante utilise une injection propriétaire de radionucléides pour traiter les tumeurs solides chez les animaux de compagnie, offrant une alternative peu invasive aux traitements traditionnels.
Cette certification marque une expansion du réseau de cliniques certifiées de Vivos, l'entreprise fournissant un soutien complet tout au long du processus de licence et de formation pour garantir une administration sûre et efficace de la thérapie IsoPet. D'autres hôpitaux vétérinaires sont actuellement en cours de certification dans le cadre de la stratégie de croissance de l'entreprise.
Vivos Inc. (OTCQB: RDGL) hat die Zertifizierung des University of Florida Veterinary Hospital bekanntgegeben, um die IsoPet® Precision Radionuclide Therapy™ anzubieten, eine gezielte Krebstherapie für Tiere. Diese innovative Therapie verwendet eine proprietäre Radionuklid-Injektion zur Behandlung von soliden Tumoren bei Haustieren und bietet eine minimalinvasive Alternative zu herkömmlichen Behandlungen.
Die Zertifizierung markiert eine Erweiterung des Netzwerks zertifizierter Kliniken von Vivos, wobei das Unternehmen umfassende Unterstützung während des Lizenzierungsprozesses und Schulungen bietet, um eine sichere und effektive Anwendung der IsoPet-Therapie zu gewährleisten. Weitere veterinärmedizinische Kliniken befinden sich derzeit im Zertifizierungsprozess als Teil der Wachstumsstrategie des Unternehmens.
- Expansion of treatment network through certification of a major veterinary institution
- Strategic growth in clinic network indicates business development progress
- Establishment of presence in academic medical setting adds credibility
- Limited current network size suggests early stage of commercialization
- Regulatory and licensing requirements may slow expansion pace
Kennewick, WA, May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that the University of Florida Veterinary Hospital has been certified to offer IsoPet® Precision Radionuclide Therapy™—a breakthrough cancer treatment for animals.
The University of Florida Veterinary Hospital, a leader in advanced veterinary care and research, is now licensed and equipped to deliver IsoPet® therapy as part of its oncology services. This certification expands the availability of a targeted, minimally invasive cancer treatment that uses a proprietary radionuclide injection to treat solid tumors in pets.
“Our goal is to grow the network of certified clinics offering IsoPet therapy across the country,” said Dr. Michael Korenko, President and CEO of Vivos Inc. “Each certification represents a step toward broader access to a treatment that is both effective and far less invasive than traditional options. The University of Florida team has demonstrated the clinical rigor and enthusiasm needed to offer this innovative therapy.”
Vivos supports each clinic through the licensing process, provides training to ensure each facility is fully prepared to administer IsoPet safely and effectively. Additional veterinary hospitals are currently undergoing the certification process.
Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ
What is IsoPet Precision Radionuclide Therapy offered by Vivos (RDGL)?
Which new facility has been certified to offer Vivos' (RDGL) IsoPet therapy in 2025?
How does Vivos (RDGL) support clinics in offering IsoPet therapy?
What is Vivos' (RDGL) strategy for expanding IsoPet therapy availability?
